Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for prolonged disorders of consciousness
NCT06389344Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine in Prolonged Disorders of Consciousness (PDOC) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Coma Recovery Scale-Revised at 3 days. Started May 2024; status: recruiting.
02
Drugs
esketamine
03
Conditions
Prolonged Disorders of Consciousness (PDOC)
Beyond the preview
Go deeper on NCT06389344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389344.